Social Links

Follow on Facebook Follow on Twitter Follow on G+

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

iHerb Rewards

 

iHerb Supplements & Natural Products

Changes in hippocampal metabolites after effective treatment for fibromyalgia: a case study

 

 

 

 

Clin J Pain. 2009 Nov-Dec;25(9):810-4.

 

Changes in hippocampal metabolites after effective treatment for fibromyalgia: a case study.

 

Wood PB, Ledbetter CR, Patterson JC 2nd. Departments of *Family Medicine, Anesthesiology and Psychiatry daggerPharmacology, Toxicology and Neuroscience double daggerPsychiatry, LSU Health Sciences Center section signPET Imaging Center, Biomedical Research Institute of NW Louisiana, Shreveport, LA.

 

 

BACKGROUND: Fibromyalgia has been associated with disrupted hippocampal brain metabolite ratios by studies using single voxel magnetic resonance spectroscopy (1H-MRS). Exposure to stress is considered a risk factor for the development and exacerbation of fibromyalgia symptoms. Basic science has demonstrated the hippocampus to be exquisitely sensitive to the effects of stressful experience, which results in changes including alterations in metabolite content and frank atrophy.

 

METHODS: This report details the case of a 47-year-old woman with fibromyalgia who was originally found to have a profound depression of the ratio of N-acetylaspartate to creatine in her right hippocampus during participation in a study to assess brain metabolite disturbances in fibromyalgia utilizing single voxel proton magnetic resonance spectroscopy. An individualized treatment strategy was developed based both on physiological abnormalities associated with the disorder and symptoms that characterized the patient's unique clinical profile.

 

RESULTS: Clinical and spectroscopic evaluation following nine months of treatment demonstrated both an improvement in her clinical profile and normalization of the NAA/Cr ratio within her right hippocampus.

 

DISCUSSION: Therapeutic strategies aimed at demonstrable lesions associated with fibromyalgia appear to represent rational targets for pharmacological intervention. The rationale for development of novel pharmacotherapies for this unusual disorder is discussed.

 

PMID: 19851163 [PubMed - in process]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:9}

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner